These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 24060335)

  • 21. Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing.
    Vogler S; Schneider P; Zimmermann N
    Pharmacoecon Open; 2019 Sep; 3(3):303-309. PubMed ID: 30721410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Cardiovascular Medicines Prices in Four European Countries.
    Mitkova Z; Vasileva M; Savova A; Manova M; Terezova S; Petrova G
    Front Public Health; 2020; 8():433. PubMed ID: 32974262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of generic drug prices in seven European countries: a methodological analysis.
    Wouters OJ; Kanavos PG
    BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries.
    Garattini L; Motterlini N; Cornago D
    Health Policy; 2008 Mar; 85(3):305-13. PubMed ID: 17928092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines.
    Twagirumukiza M; Annemans L; Kips JG; Bienvenu E; Van Bortel LM
    Trop Med Int Health; 2010 Mar; 15(3):350-61. PubMed ID: 20070634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America.
    Wirtz VJ; Santa-Ana-Tellez Y; Trout CH; Kaplan WA
    Health Policy Plan; 2012 Dec; 27(8):638-48. PubMed ID: 22367770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries.
    Leopold C; Mantel-Teeuwisse AK; Vogler S; Valkova S; de Joncheere K; Leufkens HG; Wagner AK; Ross-Degnan D; Laing R
    Bull World Health Organ; 2014 Sep; 92(9):630-640D. PubMed ID: 25378754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic prescribing of corticosteroid nasal sprays in Germany: comparison of mometasone and budesonide nasal sprays on the basis of the DDD, the PDD and reference prices.
    Becker B; Kruppert S; Kostev K
    Int J Clin Pharmacol Ther; 2013 Jan; 51(1):12-8. PubMed ID: 23110787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
    Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
    Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.
    Elek P; Takács E; Merész G; Kaló Z
    Health Policy Plan; 2017 Apr; 32(3):349-358. PubMed ID: 27697777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview of external reference pricing systems in Europe.
    Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prices & availability of common medicines at six sites in India using a standard methodology.
    Kotwani A; Ewen M; Dey D; Iyer S; Lakshmi PK; Patel A; Raman K; Singhal GL; Thawani V; Tripathi S; Laing R
    Indian J Med Res; 2007 May; 125(5):645-54. PubMed ID: 17642500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do follow-on therapeutic substitutes induce price competition between hospital medicines? Evidence from the Danish hospital sector.
    Hostenkamp G
    Health Policy; 2013 Jun; 111(1):68-77. PubMed ID: 23587548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
    Rong X; Yin J; Duan S; Sun Q; Babar ZU
    BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings.
    Russo G; McPake B
    Health Policy Plan; 2010 Jan; 25(1):70-84. PubMed ID: 19843636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.